FDA Grants Accelerated Approval to Zanidatamab-Hrii for Previously Treated Unresectable or Metastatic Her2-Positive Biliary Tract Cancer
FDA授予Zanidatamab-Hrii加速批准,用於先前接受治療的不能手術切除或轉移性Her2陽性膽道癌
FDA Grants Accelerated Approval to Zanidatamab-Hrii for Previously Treated Unresectable or Metastatic Her2-Positive Biliary Tract Cancer
FDA授予Zanidatamab-Hrii加速批准,用於先前接受治療的不能手術切除或轉移性Her2陽性膽道癌
譯文內容由第三人軟體翻譯。
使用瀏覽器的分享功能,分享給你的好友吧